麻豆果冻传媒影音

, an RNA-interfering (RNAi) therapy, reduced hard events and disease progression in transthyretin amyloidosis cardiomyopathy (ATTR-CM) regardless of background tafamidis (Vyndamax, Vyndaqel) therapy, according to HELIOS-B phase III study results announced by Alnylam Pharmaceuticals.

for primary and secondary prevention despite its prevalence drifting downward from 2012 to 2021. (Annals of Internal Medicine)

AliveCor shared the FDA clearance of the and its artificial intelligence engine, the KAI 12L, designed to detect 35 cardiac conditions including heart attacks.

The was FDA approved for the tracking of congestion in New York Heart Association class III heart failure (HF) patients, Endotronix announced.

Based on the STEP-HFpEF trial in obesity-related heart failure with preserved ejection fraction, semaglutide (Wegovy) improved quality of life for men and women alike, but . (Journal of the American College of Cardiology)

Investigators cited futility in stopping a pilot trial testing care for people with known heart failure undergoing noncardiac surgery. (Clinical Cardiology)

For patients with refractory, symptomatic left ventricular mid-cavity obstructive (LVMCO) hypertrophic cardiomyopathy, reduced LVMCO gradients and improved symptoms in a small pilot trial. (Circulation: Arrhythmia and Electrophysiology)

Virtual health coaching sessions boosted the self-care, stress, coping, and health status of . (Circulation: Heart Failure)

High lipoprotein(a), or Lp(a), was independently associated with after percutaneous coronary intervention based on a retrospective report. (European Journal of Preventive Cardiology)

A longer delay from transcatheter aortic valve replacement did not mean better surgical outcomes. (JACC: Cardiovascular Interventions)

Swedish nationwide study links with a long-term risk of cardiovascular disease by the time women reached their fifties. (European Heart Journal)

Women with cardiogenic shock were pulmonary artery catheters and mechanical circulatory support and more likely to die in-hospital than men. (Circulation: Cardiovascular Quality and Outcomes)

An elevated cardiovascular risk was associated with among Hispanics and Latinos, a finding believed to be related to changes in gut microbiota and related metabolites. (Circulation)

In mice, a year of pravastatin therapy was enough to reverse . (Journal of the American Heart Association)

Comment